Appeal No. 94-4129
Application 07/953,439
skin. As in this case, both Davis and Hille I are included in
the References Cited in Hille II. We find in Hille I an
express teaching that the reservoir layer of a transdermal
applicator for administering physostigmine may include a
polyacrylate matrix. Also, we take particular notice of two
statements in Hille II. First, at column 1, lines 26-27,
Hille II states, “Lately, galanthamine has been used in the
treatment of alcohol dependence (Opitz, K., DE 40 10 079).”
Second, at column 1, lines 40-55, Hille II states:
Accordingly, it is the object of the present
invention to provide galanthamine . . . in the form
of a transdermal therapeutic system which releases
galanthamine . . . over a period of at least 24 hours
in a controlled manner . . . .
With the present invention this object is achieved
in a surprising manner by a transdermal therapeutic
system.
This solution is remarkable all the more since the
structure of galanthamine is very similar to that of the
opiates. Opiates are considered to be a substance class
which only insufficiently penetrates human skin.
2. Findings
A. Galanthamine is useful in treating Alzheimer’s
Disease (Davis, column 1, lines 6-8).
B. Galanthamine may be administered to treat
Alzheimer’s Disease
- 5 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007